These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Present status of antileishmanial vaccines. Ghosh M; Bandyopadhyay S Mol Cell Biochem; 2003 Nov; 253(1-2):199-205. PubMed ID: 14619970 [TBL] [Abstract][Full Text] [Related]
3. Progress towards a Leishmania vaccine. Tabbara KS Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009 [TBL] [Abstract][Full Text] [Related]
4. The immunology of Leishmania infection and the implications for vaccine development. Vanloubbeeck Y; Jones DE Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504 [TBL] [Abstract][Full Text] [Related]
5. Development of a leishmaniasis vaccine: the importance of MPL. Reed SG; Coler RN; Campos-Neto A Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575 [TBL] [Abstract][Full Text] [Related]
6. Immunology of leishmaniasis. Liew FY; O'Donnell CA Adv Parasitol; 1993; 32():161-259. PubMed ID: 8237615 [No Abstract] [Full Text] [Related]
8. Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) February 13-22 and April 4-5, 1995. Grimaldi Júnior G Mem Inst Oswaldo Cruz; 1995; 90(4):553-6. PubMed ID: 8551962 [No Abstract] [Full Text] [Related]
9. The present and future of vaccination for cutaneous leishmaniasis. Greenblatt CL Prog Clin Biol Res; 1980; 47():259-85. PubMed ID: 7010374 [No Abstract] [Full Text] [Related]
10. Follow-up study of a vaccination programme against cutaneous leishmaniasis. I. Vaccination with a 5 year-old human strain of L. tropica from the Negev. Gunders AE; Naggan L; Michaeli D Trans R Soc Trop Med Hyg; 1972; 66(2):235-8. PubMed ID: 5048789 [No Abstract] [Full Text] [Related]
11. Parasite candidate vaccines: a warning from polymorphic Leishmania populations. Guerbouj S; Guizani I; Victoir K; Le Ray D; Dujardin JC Parasitol Today; 2000 Jun; 16(6):265. PubMed ID: 10827439 [No Abstract] [Full Text] [Related]
12. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Garg R; Srivastava JK; Pal A; Naik S; Dube A Vaccine; 2005 Jan; 23(9):1189-96. PubMed ID: 15629362 [TBL] [Abstract][Full Text] [Related]
13. Follow-up study of a vaccination programme against cutaneous leishmaniasis. II. Vaccination with a recently isolated strain of L. tropica from Jericho. Naggan L; Gunders AE; Michaeli D Trans R Soc Trop Med Hyg; 1972; 66(2):239-43. PubMed ID: 5048790 [No Abstract] [Full Text] [Related]
14. Olivier M; Fernandez-Prada C Future Microbiol; 2019 May; 14():559-561. PubMed ID: 31148479 [No Abstract] [Full Text] [Related]
15. Recombinant DNA-derived leishmania proteins: from the laboratory to the field. Kubar J; Fragaki K Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780 [TBL] [Abstract][Full Text] [Related]
16. [Approaches and problems in vaccine development against leishmaniasis]. Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the molecular biology of trypanosomes and leishmaniae, and its impact on the development of methods for the diagnosis and vaccination of leishmaniasis and Chagas disease. O'Daly JA Biol Res; 1993; 26(1-2):219-24. PubMed ID: 7670534 [TBL] [Abstract][Full Text] [Related]
18. Further trials of a vaccine against American cutaneous leishmaniasis. Mayrink W; Antunes CM; Da Costa CA; Melo MN; Dias M; Michalick MS; Magalhães PA; De Oliveira Lima A; Williams P Trans R Soc Trop Med Hyg; 1986; 80(6):1001. PubMed ID: 3299899 [No Abstract] [Full Text] [Related]